An Open-Label Single-Arm Phase II Study of Treatment with Neoadjuvant S-1 Plus Cisplatin for Clinical Stage III Squamous Cell Carcinoma of the Esophagus.
Mitsuro KandaMasahiko KoikeNaoki IwataDai ShimizuChie TanakaNorifumi HattoriMasamichi HayashiSuguru YamadaKenji OmaeGoro NakayamaYasuhiro KoderaPublished in: The oncologist (2020)
We demonstrate safety of NAC-SP, but not its efficacy, for patients with clinical stage III ESCC. Subsequent esophagectomy was safely performed.